search
Back to results

Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy (TE-oPTK)

Primary Purpose

Corneal Astigmatism

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Trans-epithelial PTK
EpiMaster Application Software
Sponsored by
London Vision Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Corneal Astigmatism focused on measuring Trans-epithelial phototherapeutic keratectomy, PTK, TE-PTK, Corneal epithelium, Excimer laser

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patient presents with topographic irregularly irregular astigmatism and associated quality of vision issues, where TE-PTK would be a more effective treatment than topography-guided ablation or other therapeutic treatment options.

Medically suitable for corneal laser refractive surgery.

  • Calculated residual stromal thickness ≥250 µm.
  • Subjects should be 21 years of age or older.
  • Contact lens wearers must stop wearing their contact lenses one week per decade of wear before baseline measurements in case of hard contact lenses and one week before baseline measurements in case of soft contact lenses.
  • Patient will be able to understand the patient information and willing to sign an informed consent.
  • Patient will be willing to comply with all follow-up visits and the respective examinations.

Exclusion Criteria:

  • Patient not being able to tolerate local or topical anesthesia
  • Autoimmune diseases
  • Sicca syndrome, dry eye
  • Herpes viral (herpes simplex) infections
  • Herpes zoster
  • Diabetes
  • Pregnant or nursing women (or who are planning pregnancy during the study)
  • Patients with a weight of > 135 kg
  • Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g.
  • Cataract
  • Suspected glaucoma or an intraocular pressure > 21 mm of Hg
  • Corneal disease
  • Corneal thinning disorder, e.g. keratoconus,
  • Pellucid marginal corneal degeneration
  • Dystrophy of the basal membrane
  • Corneal oedema
  • Exudative macular degeneration
  • Infection
  • Any residual, recurrent, or active abnormality of the cornea to be treated, e.g.
  • Existing corneal implant
  • Corneal lesion
  • Unstable refraction
  • Connective tissue disease
  • Dry eye

Sites / Locations

  • London Vision ClinicRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Observation Phase

Treatment Phase

Arm Description

A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.

If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.

Outcomes

Primary Outcome Measures

The tendency of manifest sphere, cylinder and axis
The correct tendency of manifest sphere, cylinder and axis should be achieved in 90% of cases, where tendency refers to: The sign of the predicted and the post-operative sphere is equal for predicted sphere values greater than absolute value 0.50 D (confidence limit) The sign of the predicted and the post-operative cylinder is equal (same cylinder format setting like e.g. plus cylinder format) for predicted cylinder values greater than absolute value 0.50 D (confidence limit) The cylinder axis of the predicted and the post-operative cylinder do not deviate by more than ±45° for predicted cylinder values greater than absolute value 0.50 D (confidence limit) In none of the cases the prediction in sphere and cylinder is more than absolute value 2.00 D off the post-operative values.
Standard deviation of SEpostop-SEpredicted
Standard deviation of SEpostop-SEpredicted at each follow-up time point (represents the scatter of the refractive outcome), where SEpredicted is the refractive outcome predicted by the EpiMaster application software.

Secondary Outcome Measures

Full Information

First Posted
February 12, 2019
Last Updated
April 19, 2022
Sponsor
London Vision Clinic
Collaborators
Optana GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT03841253
Brief Title
Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy (TE-oPTK)
Official Title
Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy (TE-oPTK)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2019 (Actual)
Primary Completion Date
March 1, 2023 (Anticipated)
Study Completion Date
March 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
London Vision Clinic
Collaborators
Optana GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study sets out to evaluate the EpiMaster application software for use in predicting the refractive change induced by a trans-epithelial phototherapeutic keratectomy (TE-PTK) procedure in eyes with irregularly irregular astigmatism. If validation criteria are met during the observational phase, the software refractive prediction will be used to plan the refractive correction in TE-PTK treatments.
Detailed Description
Complications after laser eye surgery can often result in the front surface of the eye (the cornea) becoming irregular, which causes visual symptoms such as halos, glare, starbursts, double vision, and reduced contrast sensitivity. For the past 20 years, corneal irregularities have been treated using wavefront-guided ablation, topography-guided ablation or trans-epithelial phototherapeutic keratectomy (TE-PTK). Topography-guided ablation is the most effective treatment for certain types of irregularity and works by using a laser to remove tissue from the cornea in a pattern derived from a topography scan (a measurement of the shape and curvature of the front of the eye) designed to make the corneal surface more regular. However, topography-guided ablation is less effective for other types of irregularity. In these cases, the corneal epithelium (the layer of skin on the surface of the cornea) has changed in thickness to partially hide the irregularity on the body of the cornea under the epithelium (the stroma). The epithelium does this by becoming thinner over peaks and thickening over troughs in the stroma. Therefore, the topography measurement can only detect the proportion of the irregularity that has not been hidden by the epithelium, hence reducing its effectiveness. The preferred treatment option is TE-PTK; the laser treatment is applied onto and through the epithelium, breaking through to the stroma where the epithelium is thinnest, thus removing tissue from the peaks on the stroma resulting in a more regular surface. The main weakness of TE-PTK is that it may unpredictably change the refraction to become more short-sighted or more long-sighted or change the astigmatism. To improve this, we have developed the Epimaster software that simulates a TE-PTK treatment and predicts the change in refraction. The aim of the study is to validate the refractive prediction produced by the Epimaster software by comparing this to the achieved result in the patients treated. The treatment received by the patient will be the same as has been used routinely for the past 20 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Astigmatism
Keywords
Trans-epithelial phototherapeutic keratectomy, PTK, TE-PTK, Corneal epithelium, Excimer laser

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Phase 1 will be observational comparing the software predicted refractive change to the observed refractive change. Phase 2 will use the software predicted refractive change to plan the refractive component of the treatment.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Observation Phase
Arm Type
Experimental
Arm Description
A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
Arm Title
Treatment Phase
Arm Type
Experimental
Arm Description
If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
Intervention Type
Procedure
Intervention Name(s)
Trans-epithelial PTK
Intervention Description
The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
Intervention Type
Device
Intervention Name(s)
EpiMaster Application Software
Intervention Description
The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
Primary Outcome Measure Information:
Title
The tendency of manifest sphere, cylinder and axis
Description
The correct tendency of manifest sphere, cylinder and axis should be achieved in 90% of cases, where tendency refers to: The sign of the predicted and the post-operative sphere is equal for predicted sphere values greater than absolute value 0.50 D (confidence limit) The sign of the predicted and the post-operative cylinder is equal (same cylinder format setting like e.g. plus cylinder format) for predicted cylinder values greater than absolute value 0.50 D (confidence limit) The cylinder axis of the predicted and the post-operative cylinder do not deviate by more than ±45° for predicted cylinder values greater than absolute value 0.50 D (confidence limit) In none of the cases the prediction in sphere and cylinder is more than absolute value 2.00 D off the post-operative values.
Time Frame
3-12 months
Title
Standard deviation of SEpostop-SEpredicted
Description
Standard deviation of SEpostop-SEpredicted at each follow-up time point (represents the scatter of the refractive outcome), where SEpredicted is the refractive outcome predicted by the EpiMaster application software.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patient presents with topographic irregularly irregular astigmatism and associated quality of vision issues, where TE-PTK would be a more effective treatment than topography-guided ablation or other therapeutic treatment options. Medically suitable for corneal laser refractive surgery. Calculated residual stromal thickness ≥250 µm. Subjects should be 21 years of age or older. Contact lens wearers must stop wearing their contact lenses one week per decade of wear before baseline measurements in case of hard contact lenses and one week before baseline measurements in case of soft contact lenses. Patient will be able to understand the patient information and willing to sign an informed consent. Patient will be willing to comply with all follow-up visits and the respective examinations. Exclusion Criteria: Patient not being able to tolerate local or topical anesthesia Autoimmune diseases Sicca syndrome, dry eye Herpes viral (herpes simplex) infections Herpes zoster Diabetes Pregnant or nursing women (or who are planning pregnancy during the study) Patients with a weight of > 135 kg Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g. Cataract Suspected glaucoma or an intraocular pressure > 21 mm of Hg Corneal disease Corneal thinning disorder, e.g. keratoconus, Pellucid marginal corneal degeneration Dystrophy of the basal membrane Corneal oedema Exudative macular degeneration Infection Any residual, recurrent, or active abnormality of the cornea to be treated, e.g. Existing corneal implant Corneal lesion Unstable refraction Connective tissue disease Dry eye
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Timothy J Archer, PhD
Phone
02072241005
Email
tim@londonvisionclinic.com
Facility Information:
Facility Name
London Vision Clinic
City
London
ZIP/Postal Code
W1G 7LA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Archer, MA
Phone
02072241005
Email
tim@londonvisionclinic.com
First Name & Middle Initial & Last Name & Degree
Dan Z Reinstein, MD, MA, FRCOphth

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Participant data will not be shared with other researchers.
Citations:
PubMed Identifier
22947295
Citation
Reinstein DZ, Archer TJ, Gobbe M. Refractive and topographic errors in topography-guided ablation produced by epithelial compensation predicted by 3D Artemis VHF digital ultrasound stromal and epithelial thickness mapping. J Refract Surg. 2012 Sep;28(9):657-63. doi: 10.3928/1081597X-20120815-02.
Results Reference
background
PubMed Identifier
23909779
Citation
Reinstein DZ, Archer TJ, Gobbe M. Improved effectiveness of transepithelial PTK versus topography-guided ablation for stromal irregularities masked by epithelial compensation. J Refract Surg. 2013 Aug;29(8):526-33. doi: 10.3928/1081597X-20130719-02.
Results Reference
background
PubMed Identifier
24972404
Citation
Reinstein DZ, Archer TJ, Dickeson ZI, Gobbe M. Transepithelial phototherapeutic keratectomy protocol for treating irregular astigmatism based on population epithelial thickness measurements by artemis very high-frequency digital ultrasound. J Refract Surg. 2014 Jun;30(6):380-7. doi: 10.3928/1081597X-20140508-01.
Results Reference
background
PubMed Identifier
28991341
Citation
Guglielmetti S, Kirton A, Reinstein DZ, Carp GI, Archer TJ. Repair of Irregularly Irregular Astigmatism by Transepithelial Phototherapeutic Keratectomy. J Refract Surg. 2017 Oct 1;33(10):714-719. doi: 10.3928/1081597X-20170721-04.
Results Reference
background
PubMed Identifier
17081871
Citation
Reinstein DZ, Archer T. Combined Artemis very high-frequency digital ultrasound-assisted transepithelial phototherapeutic keratectomy and wavefront-guided treatment following multiple corneal refractive procedures. J Cataract Refract Surg. 2006 Nov;32(11):1870-6. doi: 10.1016/j.jcrs.2006.07.016.
Results Reference
background

Learn more about this trial

Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy (TE-oPTK)

We'll reach out to this number within 24 hrs